Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of BMS-582664 versus doxorubicin in unresectable hepatocellular carcinoma
2006-001012-68Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brivanib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: 6-month progression-free survival rate (BMS-582664 arm), 6-month progression-free survival rate (doxorubicin arm) and 1 more. Started Nov 2006; status: terminated.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-001012-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001012-68.